Targeted treatment methods for breast cancer

Targeted therapy is aimed at the site of tumor occurrence, using drugs that can bind to tumor cells. It targets diseased cells and has the characteristics of precise positioning compared with traditional radiotherapy and chemotherapy. Targeted therapy is not suitable for all breast cancer patients. At present, targeted drugs for breast cancer include lapatinib, pertuzumab, etc. Endocrine therapy patients are prone to drug resistance. Pabo drugs and m-Tor pathway inhibitors play a certain role in reversing endocrine therapy resistance. Please combine the specific medication with the clinical situation and follow the doctor's face-to-face consultation guidance.

Side effects of targeted therapy for breast cancer

Targeted therapy drugs for breast cancer have less toxicity and side effects than radiotherapy and chemotherapy drugs. For example, Herceptin is a targeted therapy drug for breast cancer, which has minimal gastrointestinal and bone marrow reactions, but it has some cardiotoxicity, and rarely severe patients may die. Cardiac assessment tests are performed before targeted therapy, and heart monitoring is performed during treatment. Doctors determine whether the patient is suitable for this targeted therapy drug and when to start or terminate treatment based on the patient's heart condition. The side effects of another targeted breast cancer drug, Everolimus, are mainly severe oral mucosal reactions.

Cost of targeted therapy for breast cancer

The cost of targeted treatment for breast cancer is determined according to the patient's condition, course of treatment and drug manufacturer. There are many targeted treatments for breast cancer, and the most commonly used HER-2 treatment can significantly improve the efficacy and prolong the patient's survival. Due to the increase in manufacturers and the improvement of national medical insurance policies, the cost of HER-2 resistant drug treatment has dropped significantly, and the current cost of resistant drugs has dropped significantly. HER-2 Herceptin is the most commonly used drug for treatment, costing about 7,000 yuan, about once a month, for 1 year. In addition to HER-2 treatment drugs, there are also treatment drugs for BRCA gene mutation patients. The PARP inhibitor Olaparib is currently not available in China and costs more than Herceptin. Please combine the specific medication with the clinical practice and follow the doctor's face-to-face consultation guidance.